Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

Slides:

Advertisements

Similar presentations

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

Advertisements

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

From: Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes Ann Intern Med.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Dose response of pAGA1 and pFIG1 induction

Differences in the glycated hemoglobin (HbA1c) levels.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Clarke Error Grids (ISO15197; 2013) of StatStrip and coincident FSLTab-CGM arm (upper left panel), FSL-CGM abdomen (lower left panel) and FSLC readings.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Glucose, insulin, and AGE levels during an OGC before and after RT

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Continuous associations

The underlying physiological basis of the HOMA model.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Incidence of childhood type 1 diabetes in Western Australia from 1985 through Incidence of childhood type 1 diabetes in Western Australia from 1985.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Mean (± SE) plasma glucose concentrations, symptom scores, plasma epinephrine and glucagon concentrations, and relative rCBF (as measured by PET counts)

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Box-and-whisker plots of SMAP assessed by AUC in diabetic patients with normoalbuminuria and albuminuria, treated with or without aspirin. Box-and-whisker.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Distribution of daily frequency of BGM

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Western blot analysis of plasma proteins from two-dimensional gel electrophoresis. Western blot analysis of plasma proteins from two-dimensional gel electrophoresis.

Postoperative blood glucose levels and total insulin requirement.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Manhattan plot of 11,628 m/z features comparing participants who developed incident T2D versus those who did not. Manhattan plot of 11,628 m/z features.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

A: Glucose levels during basal-bolus and SSI treatment.

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration (right panel) in the clamp studies after subcutaneous injection of 0.3, 0.6, and 1.2 units · kg−1 glargine (upper, middle, and lower panels) in subjects with type 1 diabetes. Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration (right panel) in the clamp studies after subcutaneous injection of 0.3, 0.6, and 1.2 units · kg−1 glargine (upper, middle, and lower panels) in subjects with type 1 diabetes. Medians (solid lines) and 25th–75th percentiles are given (dotted and dashed lines). LLOQ: 33 pmol · L−1 (solid line) for M1. Plasma glargine and M2 concentrations are not presented since its concentrations nearly always fall below LLOQ (see results). Geremia B. Bolli et al. Dia Care 2012;35:2626-2630 ©2012 by American Diabetes Association